- Home
- BNTC vs TSHA Comparison
BNTC vs TSHA Comparison
Compare BNTC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTC | TSHA |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.0M | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BNTC | TSHA |
|---|---|---|
| Price | $11.97 | $5.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $28.25 | $10.22 |
| AVG Volume (30 Days) | 229.1K | ★ 3.4M |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.70 | $1.05 |
| 52 Week High | $17.15 | $5.95 |
Technical Indicators
Market Signals| Indicator | BNTC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 67.47 |
| Support Level | $12.78 | $5.22 |
| Resistance Level | $13.68 | $5.54 |
| Average True Range (ATR) | 0.76 | 0.32 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 22.20 | 92.43 |
Price Performance
Historical ComparisonAbout BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.